A Massachusetts federal court has dismissed claims against a biopharmaceutical company, finding statements it released about a gene therapy drug didn’t violate securities laws.

In an opinion signed March 31 and made public on April 3, U.S. District Judge Angel Kelley wrote that Latham & Watkins-repped Homology Medicines Inc. “had no duty to disclose data in real time” and that the case stands in contrast to others in which courts found in plaintiffs’ favor because the information Homology didn’t disclose doesn’t contradict the information it did.